MannKind (MNKD) CFO receives performance-based RSUs and long-term stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MannKind Corp’s Chief Financial Officer Christopher B. Prentiss received new equity awards. He was granted 221,000 performance-based restricted stock units, each representing a right to one share of common stock, and 217,000 employee stock options with a $2.44 exercise price, all held directly.

The performance units vest on January 15, 2029, with actual payout from 0% to 300% of the 221,000-share target based on MannKind’s total shareholder return from April 1, 2026 through December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index. The options vest 25% on March 23, 2027 and then 1/16 quarterly until fully vested, and expire on March 23, 2036.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Prentiss Christopher B

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Performance Restricted Stock Unit	221,000	$0.00	--
Grant/Award	Employee Stock Option (right to buy)	217,000	$0.00	--

Holdings After Transaction: Performance Restricted Stock Unit — 221,000 shares (Direct); Employee Stock Option (right to buy) — 217,000 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/25/2026 - 09:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prentiss Christopher B

(Last)

(First)

(Middle)

1 CASPER STREET

(Street)

DANBURY

CONNECTICUT

06810

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MANNKIND CORP [ MNKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Restricted Stock Unit	⁽¹⁾	03/23/2026		A		221,000		⁽²⁾	⁽²⁾	Common Stock, $0.01 Par Value	221,000	$0	221,000	D
Employee Stock Option (right to buy)	$2.44	03/23/2026		A		217,000		03/23/2027⁽³⁾	03/23/2036	Common Stock, $0.01 Par Value	217,000	$0	217,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

2. The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

3. 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.

	/s/ Christopher Prentiss	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did MannKind (MNKD) grant to its CFO in this Form 4?

MannKind granted CFO Christopher B. Prentiss 221,000 performance-based restricted stock units and 217,000 employee stock options. Each restricted unit represents one share of common stock, while the options allow future share purchases at a fixed $2.44 exercise price if vesting conditions are satisfied.

How do the MannKind (MNKD) performance-based restricted stock units vest for the CFO?

The 221,000 performance-based restricted stock units vest on January 15, 2029, but the actual shares delivered depend on performance. Payout ranges from 0% to 300% of target, based on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index over a defined measurement period.

What performance period determines the MannKind (MNKD) TSR-based award for the CFO?

The performance award is based on total shareholder return from April 1, 2026 through December 31, 2028. MannKind’s percentile ranking versus the Russell 3000 Pharmaceutical & Biotechnology Index during this period determines whether 0%, 50%, 100%, 200%, or 300% of the target units are delivered.

What is the vesting schedule for the MannKind (MNKD) stock options granted to the CFO?

The 217,000 employee stock options vest 25% on March 23, 2027, with the remaining 75% vesting in equal 1/16 installments quarterly thereafter. These options carry a $2.44 exercise price and expire on March 23, 2036 if not exercised after vesting.

What does each MannKind (MNKD) restricted stock unit represent in the CFO’s award?

Each restricted stock unit represents a contingent right to receive one share of MannKind common stock. Delivery depends on vesting conditions, including time-based and performance-based criteria, particularly total shareholder return versus a pharmaceutical and biotechnology index during the specified measurement period.